Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (10)
Type
Type
Guidance (295)
Quality standard (31)
Guidance programme
Guidance programme
Diagnostics guidance (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (6)
Medical technologies guidance (7)
Technology appraisal guidance (280)
Apply filters
Showing 41 to 50 of 326
Guidance and quality standards awaiting development
Title
Type
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592
Technology appraisal guidance
Botulinum toxin type A for preventing episodic migraine ID 6450
Technology appraisal guidance
Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over ID 6448
Technology appraisal guidance
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]
Technology appraisal guidance
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma ID 6437
Technology appraisal guidance
Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over ID6486
Technology appraisal guidance
Bupivacaine–meloxicam for treating postoperative pain [ID2728]
Technology appraisal guidance
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]
Technology appraisal guidance
Cabozantinib for treating advanced pancreatic or extra-pancreatic neuroendocrine tumours that have progressed after systemic treatment TSID 12078
Technology appraisal guidance
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]
Technology appraisal guidance
Previous page
1
…
3
4
Current page
5
6
7
…
33
Page
5
of
33
Next page
Results per page
10
25
50
All
Back to top